- Home
- APCX vs CLDI Comparison
APCX vs CLDI Comparison
Compare APCX & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APCX
- CLDI
- Stock Information
- Founded
- APCX 2006
- CLDI 2014
- Country
- APCX United States
- CLDI United States
- Employees
- APCX N/A
- CLDI N/A
- Industry
- APCX Finance: Consumer Services
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APCX Finance
- CLDI Health Care
- Exchange
- APCX Nasdaq
- CLDI Nasdaq
- Market Cap
- APCX 12.0M
- CLDI 14.0M
- IPO Year
- APCX N/A
- CLDI N/A
- Fundamental
- Price
- APCX $0.33
- CLDI $0.48
- Analyst Decision
- APCX
- CLDI Strong Buy
- Analyst Count
- APCX 0
- CLDI 2
- Target Price
- APCX N/A
- CLDI $15.00
- AVG Volume (30 Days)
- APCX 115.6K
- CLDI 386.9K
- Earning Date
- APCX 05-13-2025
- CLDI 05-13-2025
- Dividend Yield
- APCX N/A
- CLDI N/A
- EPS Growth
- APCX N/A
- CLDI N/A
- EPS
- APCX N/A
- CLDI N/A
- Revenue
- APCX $276,000.00
- CLDI N/A
- Revenue This Year
- APCX N/A
- CLDI N/A
- Revenue Next Year
- APCX N/A
- CLDI N/A
- P/E Ratio
- APCX N/A
- CLDI N/A
- Revenue Growth
- APCX N/A
- CLDI N/A
- 52 Week Low
- APCX $0.31
- CLDI $0.35
- 52 Week High
- APCX $1.49
- CLDI $4.90
- Technical
- Relative Strength Index (RSI)
- APCX 43.69
- CLDI 39.82
- Support Level
- APCX $0.33
- CLDI $0.41
- Resistance Level
- APCX $0.42
- CLDI $0.52
- Average True Range (ATR)
- APCX 0.04
- CLDI 0.07
- MACD
- APCX 0.00
- CLDI 0.02
- Stochastic Oscillator
- APCX 19.35
- CLDI 69.70
About APCX AppTech Payments Corp.
AppTech Payments Corp is a FinTech company utilizing various payment processing and digital banking technologies to complement core merchant services capabilities. The company's patented and proprietary software will provide progressive and adaptable products that are available through a suite of synergistic offerings directly to merchants, banking institutions, and business enterprises. It is developing a secure digital payment and banking platform that powers commerce experiences for clients and customers. Based upon industry standards for payment and banking protocols, the company will offer standalone products and fully integrated solutions that deliver unparalleled payments, banking, and financial services experiences.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.